Patents by Inventor Arron Hearn

Arron Hearn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180193454
    Abstract: Improved anti-CD154 antibodies are provided herein which have improved therapeutic potency, in vivo half-life and ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation, transplant recipients, fibrosis and allergic disorders is disclosed herein.
    Type: Application
    Filed: July 13, 2016
    Publication date: July 12, 2018
    Inventors: Jay Rothstein, Robert George Edward Holgate, Arron Hearn
  • Patent number: 9976131
    Abstract: The present application relates to modified T cell epitopes derived from fungal ribotoxins, including ?-sarcin, clavin, gigantin, mitogillin, and restrictocin, as well as modified ribotoxin molecules comprising one or more of the modified epitopes. The modified ribotoxin molecules inhibit protein synthesis, like the wild type ribotoxins, but exhibit reduced immunogenicity as compared to the corresponding wild type ribotoxin. Another aspect relates to a fusion protein which comprises a modified ribotoxin fused or conjugated or otherwise linked to a targeting molecule that is effective for binding a target of interest. Another aspect relates to the use of the modified ribotoxin or fusion protein for treating or managing a disease or condition.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: May 22, 2018
    Assignee: RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventors: Kurt R. Gehlsen, Timothy David Jones, Francis Joseph Carr, Arron Hearn
  • Publication number: 20170204387
    Abstract: The present application relates to modified T cell epitopes derived from fungal ribotoxins, including ?-sarcin, clavin, gigantin, mitogillin, and restrictocin, as well as modified ribotoxin molecules comprising one or more of the modified epitopes. The modified ribotoxin molecules inhibit protein synthesis, like the wild type ribotoxins, but exhibit reduced immunogenicity as compared to the corresponding wild type ribotoxin. Another aspect relates to a fusion protein which comprises a modified ribotoxin fused or conjugated or otherwise linked to a targeting molecule that is effective for binding a target of interest. Another aspect relates to the use of the modified ribotoxin or fusion protein for treating or managing a disease or condition.
    Type: Application
    Filed: February 13, 2017
    Publication date: July 20, 2017
    Inventors: Kurt R. Gehlsen, Timothy David Jones, Francis Joseph Carr, Arron Hearn
  • Patent number: 9603911
    Abstract: The present application relates to modified T cell epitopes derived from fungal ribotoxins, including a-sarcin, clavin, gigantin, mitogillin, and restrictocin, as well as modified ribotoxin molecules comprising one or more of the modified epitopes. The modified ribotoxin molecules inhibit protein synthesis, like the wild type ribotoxins, but exhibit reduced immunogenicity as compared to the corresponding wild type ribotoxin. Another aspect relates to a fusion protein which comprises a modified ribotoxin fused or conjugated or otherwise linked to a targeting molecule that is effective for binding a target of interest. Another aspect relates to the use of the modified ribotoxin or fusion protein for treating or managing a disease or condition.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: March 28, 2017
    Assignee: RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventors: Kurt R. Gehlsen, Timothy David Jones, Francis Joseph Carr, Arron Hearn
  • Publication number: 20160106819
    Abstract: The present application relates to modified T cell epitopes derived from fungal ribotoxins, including a-sarcin, clavin, gigantin, mitogillin, and restrictocin, as well as modified ribotoxin molecules comprising one or more of the modified epitopes. The modified ribotoxin molecules inhibit protein synthesis, like the wild type ribotoxins, but exhibit reduced immunogenicity as compared to the corresponding wild type ribotoxin. Another aspect relates to a fusion protein which comprises a modified ribotoxin fused or conjugated or otherwise linked to a targeting molecule that is effective for binding a target of interest. Another aspect relates to the use of the modified ribotoxin or fusion protein for treating or managing a disease or condition.
    Type: Application
    Filed: March 3, 2014
    Publication date: April 21, 2016
    Inventors: Kurt R. Gehlsen, Timothy David Jones, Francis Joseph Carr, Arron Hearn